United States

Aurinia Pharmaceuticals Inc (AUPH.OQ)

AUPH.OQ on NASDAQ Stock Exchange Global Market

3:59pm EST
Change (% chg)

$0.17 (+3.29%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Aurinia reports Q3 loss per share $0.16
Tuesday, 14 Nov 2017 04:00pm EST 

Nov 14 (Reuters) - Aurinia Pharmaceuticals Inc :Aurinia reports third quarter 2017 financial results and provides operational highlights.Aurinia Pharmaceuticals Inc - ‍Aurora phase III trial in lupus nephritis on track​.Q3 loss per share $0.16.Aurinia Pharmaceuticals - Believe​ co have sufficient financial resources to fund LN program,conduct work on new indications & fund operations into 2020.  Full Article

Robert Duggan reports 5.9 pct stake in Aurinia Pharmaceuticals - SEC filing‍​
Monday, 23 Oct 2017 05:43pm EDT 

Oct 23 (Reuters) - Aurinia Pharmaceuticals Inc : :Robert Duggan reports 5.9 percent stake in Aurinia Pharmaceuticals Inc as on October 19, 2017 - SEC filing‍​.Robert Duggan had previously reported 7.2 percent stake in Aurinia Pharmaceuticals Inc as on April 21, 2017.  Full Article

Aurinia Pharmaceuticals plans to expand voclosoprin renal franchise
Friday, 20 Oct 2017 08:00am EDT 

Oct 20 (Reuters) - Aurinia Pharmaceuticals Inc :Aurinia Pharmaceuticals Inc - ‍ plans to expand voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease​.Aurinia Pharmaceuticals - ‍ plans to evaluate proprietary nanomicellar voclosporin ophthalmic solution for treatment of keratoconjunctivitis sicca/ DES.Aurinia Pharmaceuticals - ‍a phase II proof of concept clinical trial for voclosporin in FSGS and MCD patients will be initiated in first half of 2018​.  Full Article

Aurinia Pharma announces 48-week results from study of voclosporin
Monday, 27 Mar 2017 06:30am EDT 

Aurinia Pharmaceuticals Inc : Aurinia Pharmaceuticals-announces 48-week results from “Aurinia early urinary protein reduction predicts response study” of voclosporin for treatment of lupus nephritis . Aurinia Pharmaceuticals Inc says study successfully achieved primary objective - SEC filing .Aurinia Pharmaceuticals says no new safety signals were observed with use of voclosporin in ln patients; voclosporin was well-tolerated.  Full Article

Aurinia says receives FDA end of phase 2 meeting minutes
Tuesday, 13 Dec 2016 08:00am EST 

Aurinia Pharmaceuticals Inc : Aurinia confirms receipt of FDA end of phase 2 meeting minutes . Trial on track to commence in Q2 2017 . Single phase 3 clinical trial to be conducted with 23.7 mg bid voclosporin for treatment of active lupus nephritis .Aurinia believes phase 3 clinical trial will support a new drug application (nda) submission.  Full Article